Predicting brain metastases of breast cancer based on serum S100B and serum HER2
Predicting brain metastases of breast cancer based on serum S100B and serum HER2
复制标题
DOI：
10.3892/ol.2013.1536
复制
发表时间：
2013-11-01
期刊：
影响因子：
2.9
通讯作者：
Jakobsen, Anders
中科院分区：
文献类型：
--
作者：
Bechmann, Troels;Madsen, Jonna Skov;Jakobsen, Anders
脑转移是乳腺癌发病率和死亡率的主要原因。本研究的目的是评估基于血清S100B和人表皮生长因子受体2(HER2)预测脑转移的价值。本次研究共纳入107名乳腺癌患者，这些患者来自两项前瞻性队列研究，要么血清HER2水平升高15 ng/ml，要么经磁共振成像(MRI)或计算机断层扫描(CT)证实有脑转移。排除6例患者后，其余101例患者被分成两组：0组(n=55)MRI结果正常的患者；1组(n=46)脑转移患者。对两组患者的血清S100B和HER2水平进行分析，发现两组间血清HER2和S100B水平差异无统计学意义(P=0.060或P=0.623)。单因素分析显示脑转移瘤的预后因素与全身疾病显著相关(P30 ng/ml，P=0.002)。只有全身性疾病(P30 ng/ml)与脑转移风险的增加相关，这需要进一步的研究。
Brain metastases are a major cause of morbidity and mortality in breast cancer. The aim of the current study was to evaluate the prediction of brain metastases based on serum S100B and human epidermal growth factor receptor 2 (HER2). A total of 107 breast cancer patients were included in the current study from two prospective cohort studies with either elevated serum HER2 levels >15 ng/ml or brain metastases verified by magnetic resonance imaging (MRI) or computer tomography (CT). Following the exclusion of six patients, the remaining 101 patients were divided into two groups: Group 0 (n=55), patients with normal MRI results; and group 1 (n=46), patients with brain metastases. The levels of serum S100B and HER2 in the two groups were analyzed prior to MRI or CT of the brain, and no significant differences were identified in the serum HER2 (P=0.060) or S100B levels (P=0.623) between the groups. The univariate analysis of prognostic factors for brain metastases showed a significant correlation with systemic disease (P30 ng/ml (P=0.002). Only systemic disease (P30 ng/ml were identified to correlate with increased risk of brain metastases, which calls for further investigation.